Kailera Therapeutics (NASDAQ:KLRA) Issues Earnings Results, Beats Expectations By $0.81 EPS

Kailera Therapeutics (NASDAQ:KLRA) posted its quarterly earnings results on Wednesday. The company reported ($0.74) earnings per share for the quarter, beating analysts’ consensus estimates of ($1.55) by $0.81, FiscalAI reports.

Kailera Therapeutics Stock Performance

Shares of Kailera Therapeutics stock traded up $0.80 during trading on Friday, reaching $12.97. The company’s stock had a trading volume of 733,038 shares, compared to its average volume of 883,973. The firm’s 50-day moving average price is $12.89. Kailera Therapeutics has a 52 week low of $9.76 and a 52 week high of $28.23. The firm has a market capitalization of $1.68 billion and a price-to-earnings ratio of -0.00.

Analyst Upgrades and Downgrades

Separately, Weiss Ratings upgraded shares of Kailera Therapeutics from a “sell (d-)” rating to a “sell (d)” rating in a report on Wednesday, October 21st. One equities research analyst has rated the stock with a Strong Buy rating, five have issued a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $42.75.

Institutional Trading of Kailera Therapeutics

Hedge funds and other institutional investors have recently bought and sold shares of the business. Atlas Venture Life Science Advisors LLC bought a new position in shares of Kailera Therapeutics during the second quarter worth approximately $113,923,000. Wellington Management Group LLP acquired a new stake in shares of Kailera Therapeutics in the second quarter valued at approximately $64,308,000. Frazier Life Sciences Management L.P. acquired a new stake in shares of Kailera Therapeutics in the second quarter valued at approximately $24,233,000. State Street Corp bought a new stake in shares of Kailera Therapeutics in the second quarter valued at approximately $19,126,000. Finally, Mirador Capital Partners LP bought a new stake in shares of Kailera Therapeutics in the third quarter valued at approximately $666,000.

Kailera Therapeutics Company Profile

Kailera Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on developing treatments for obesity and related metabolic diseases.

The company’s activities center on the research and development of potential pharmaceutical therapies intended to address chronic weight management and associated health conditions. Its products remain in development and are subject to clinical, regulatory and commercial milestones.

Publicly available information about Kailera Therapeutics’ specific product candidates, operating geographies and leadership is limited.